" class="no-js "lang="en-US"> Thomas Lingelbach - Medtech Alert
Saturday, August 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Thomas Lingelbach

Thomas Lingelbach

About Thomas Lingelbach

Thomas Lingelbach was CEO of Intercell and founding CEO of Valneva.

He is an established vaccine industry leader with breadth of experience. Prior to Valneva Thomas had senior & executive management roles with Intercell, Novartis and Chiron.

During his 30 years in vaccines, he held a variety of positions from product development to commercialization with a strong emphasis on technical development & operations.

In different capacities, he contributed to the successful development and licensure of more than ten vaccines.

Thomas Lingelbach holds an engineering degree, specialized in bioprocess engineering and complemented his education with a business administration program.

He is a German national, born in 1963.

Related Story

Diseases

 Pfizer Inc. - Valneva and Pfizer Enter Into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 | Pharmtech Focus

Valneva and Pfizer Enter Into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

June 20 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced […]